Live tape
Top 8, mentions 7d11,443SPCX2,424 mentions▲ +0.08GOOGL1,984 mentions▲ +0.02META1,790 mentions▲ +0.04TSLA1,702 mentions▲ +0.05NFLX973 mentions▲ +0.03QQQ886 mentions▲ +0.05AMZN843 mentions▲ +0.06NVDA841 mentions▲ +0.06

Equity · Healthcare

ZYME

NASDAQ

Zymeworks (ZYME)

$27.51 −0.24% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 23, 2026
Price · Chart
29 sessions
$32 $24 13 Aug 23 Sep

The line runs $26 on 13 August through $27.51 on 23 September, on a scale from $24 to $32. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 29 sessions, 13 Aug – 23 Sep 2026
Market cap $2.0B
52-week range $15.89 – $31.05
Avg volume 41.7K

as of Sep 23, 2026

Zymeworks (ZYME) insider trades

SEC Form 4 · last 90 days · newest reported trade 9 Oct 2026

In the 90 days to 26 Oct 2026, Zymeworks insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 22 Dec 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 1
Net sold $358K
Non-trade filings 1
Date Insider Type Shares Value
09 Oct 2026 Schayowitz Adam EVP, Head of R&D Sell 13,832 $358K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
09 Oct 2026 Schayowitz Adam EVP, Head of R&D Option exercise 37,037

Zymeworks (ZYME) reported financials

SEC EDGAR XBRL SEC EDGAR

Zymeworks reported revenue of $106.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$81.1M.

Figure Reported Period
Revenue $106.0M 31 Dec 2025 fiscal year
Net income −$81.1M 31 Dec 2025 fiscal year
Diluted EPS −$1.08 31 Dec 2025 fiscal year
Total assets $397.0M 30 Jun 2026 at period end
Total equity $80.4M 30 Jun 2026 at period end

Zymeworks (ZYME) earnings

SEC EDGAR

Zymeworks last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.62; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.62 $5M
31 Mar 2026 Q1 2026 −$0.59 $2M
31 Dec 2025 FY 2025 −$1.08 $106M
30 Sep 2025 Q3 2025 −$0.26 $28M
30 Jun 2025 Q2 2025 $0.03 $49M
31 Mar 2025 Q1 2025 −$0.30 $27M
31 Dec 2024 FY 2024 −$1.62 $76M
30 Sep 2024 Q3 2024 −$0.39 $16M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Zymeworks (ZYME) institutional holders (13F)

SEC Form 13F SEC EDGAR

8 of the 45 institutional funds we track reported a Zymeworks position for the quarter ended 30 Jun 2026 — a combined $41.9M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Citadel Advisors Held (±25%) −20.5% shares 914,136 $23.9M
Man Group Held (±25%) +11.0% shares 210,779 $5.5M
D. E. Shaw & Co. Trimmed −38.5% shares 144,807 $3.8M
AQR Capital Management Held (±25%) +22.7% shares 111,282 $2.9M
Two Sigma Investments New position 71,874 $1.9M
Fisher Asset Management Trimmed −30.2% shares 70,775 $1.9M
Marshall Wace Added +27.1% shares 40,948 $1.1M
Tudor Investment Corp Held (±25%) −1.1% shares 36,471 $953K

Zymeworks (ZYME) fails-to-deliver

SEC CNS data SEC

On 21 Sep 2026, 17,984 shares of Zymeworks failed to deliver (about $478K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
21 Sep 2026 17,984 $478K 0.025%
18 Sep 2026 1,155 $32K 0.002%

Zymeworks (ZYME): frequently asked questions

From live data

Have Zymeworks insiders bought or sold shares recently?

In the 90 days to 26 Oct 2026, Zymeworks insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 22 Dec 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade.

How many institutions hold Zymeworks?

8 of the 45 institutional funds we track reported a Zymeworks position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Zymeworks had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Zymeworks is dated 21 Sep 2026, when 17,984 shares failed to deliver.

When did Zymeworks last report earnings?

Zymeworks last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.62; no next date is announced in SEC filings yet.

What exchange is Zymeworks listed on?

Zymeworks trades on NASDAQ under the ticker ZYME.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings